Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Caplin Point Laboratories Limited

Market Cap 183B 1.93B 1.67B 1.53B 1.44B 2.69B 2.73B 18.12B 7.07B 89.21B 7.24B 7.08B 309B P/E Ratio 2026
17.9x
P/E Ratio 2027 * 25.7x
Enterprise Value 183B 1.93B 1.67B 1.53B 1.44B 2.69B 2.73B 18.12B 7.07B 89.21B 7.24B 7.08B 309B EV / Sales 2026
5.23x
EV / Sales 2027 * 7.37x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.17%
1 day+3.45%
1 week+18.70%
Current month+18.78%
1 month+30.84%
3 months+45.09%
6 months+22.86%
Current year+30.96%
1 week 2,006.45
Extreme 2006.45
2,424
1 month 1,948.85
Extreme 1948.85
2,424
Current year 1,502.45
Extreme 1502.45
2,424
1 year 1,502.45
Extreme 1502.45
2,424
3 years 781.25
Extreme 781.25
2,636
5 years 575
Extreme 575
2,636
10 years 180
Extreme 180
2,636
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Director/Board Member 71 2015-03-27
Change 5-day change 1-year change 3-year change Capi.($)
+3.45%+18.70%+12.66%+195.74% 1.93B
+0.75%+1.43%+7.10%+82.95% 45.63B
-0.20%-3.59%+40.67%+83.59% 33.53B
+0.44%-0.85%-7.69%+41.56% 11.81B
-0.11%+1.44%+13.31%+113.41% 11.69B
+0.59%+0.78%+36.70%+127.43% 9.12B
+2.40%+0.08%+18.35%+44.00% 7.16B
-1.12%-0.56%+41.74%-17.87% 6.49B
+1.37%+0.35%+30.18%+234.95% 6.45B
+0.51%-3.04%-43.06%-5.07% 5.16B
Average +0.81%+1.80%+15.00%+90.07% 13.9B
Weighted average by Cap. +0.47%-0.03%+17.89%+83.71%

Financials

2026 2027 *
Net sales 21.28B 224M 193M 178M 167M 313M 317M 2.1B 820M 10.36B 840M 822M 35.86B 24.88B 262M 226M 208M 195M 365M 371M 2.46B 959M 12.11B 982M 961M 41.93B
Net income 6.16B 64.83M 55.99M 51.6M 48.3M 90.51M 91.91M 609M 238M 3B 243M 238M 10.38B 7.13B 74.99M 64.77M 59.68M 55.86M 105M 106M 705M 275M 3.47B 281M 275M 12.01B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
26-06-12 2,411.30 +3.45% 11,551
26-06-11 2,330.80 +0.99% 14,610
26-06-10 2,308.00 +2.23% 77,262
26-06-09 2,257.60 +7.00% 29,424
26-06-08 2,110.00 +3.87% 19,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,411.30INR
Average target price
2,505.00INR
Spread / Average Target
+3.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 524742 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!